Holen Sie sich die Stockscreener-App
2.69
0.00%
0.00
Schlusskurs vom Vortag:
$2.69
Offen:
$2.72
24-Stunden-Volumen:
684.51K
Relative Volume:
0.57
Marktkapitalisierung:
$461.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-8.1515
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
-4.61%
1M Leistung:
-3.93%
6M Leistung:
-39.96%
1J Leistung:
-43.96%
1-Tages-Spanne:
$2.645
$2.73
1-Wochen-Bereich:
$2.645
$2.91
52-Wochen-Spanne:
$2.59
$5.70
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.69 | 461.65M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara Inc. Awards Stock Options and RSUs to New Employees - MSN
SVRASavara Inc Latest Stock News & Market Updates - StockTitan
Savara Announces New Employment Inducement Grant - Milton Daily Standard
Savara's Latest Executive Compensation Package Revealed: Key Details on New Employee Stock Awards - StockTitan
A company insider recently sold 25,000 shares of Savara Inc [SVRA]. Should You Sale? - Knox Daily
SG Americas Securities LLC Has $158,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
SVRA’s latest rating updates from top analysts. - Knox Daily
Positive Signs As Multiple Insiders Buy Savara Stock - Yahoo Finance UK
Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN
Analysts Predict How High Savara Inc (SVRA) Will Go. - Stocks Register
JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Molgramostim shows promise in rare lung disease treatment - MSN
SVRA stock touches 52-week low at $2.6 amid market challenges - MSN
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire
Savara Announces Participation in Upcoming Healthcare Investor Conferences - The Bakersfield Californian
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Title: Savara Inc. Approves 2025 Executive Officers’ Target Bonus Amounts - Defense World
Savara sets executive bonus targets for 2025 - MSN
Savara sets executive bonus targets for 2025 By Investing.com - Investing.com Australia
Savara Sets 2025 Executive Bonus Targets - TipRanks
Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - MSN
Savara (NASDAQ:SVRA) Shares Up 8.1%Should You Buy? - MarketBeat
Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market - TipRanks
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses - Simply Wall St
Savara Inc (NASDAQ:SVRA) Shares Sold by Jane Street Group LLC - Defense World
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges By Investing.com - Investing.com South Africa
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges - Investing.com Australia
Savara Inc. Grants Inducement Awards to New Employees - MSN
Principal Financial Group Inc. Sells 7,607 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):